- Home
- CRGX vs DHF Comparison
CRGX vs DHF Comparison
Compare CRGX & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- DHF
- Stock Information
- Founded
- CRGX 2021
- DHF 1998
- Country
- CRGX United States
- DHF United States
- Employees
- CRGX N/A
- DHF N/A
- Industry
- CRGX
- DHF Finance Companies
- Sector
- CRGX
- DHF Finance
- Exchange
- CRGX Nasdaq
- DHF Nasdaq
- Market Cap
- CRGX 180.4M
- DHF 183.3M
- IPO Year
- CRGX 2023
- DHF N/A
- Fundamental
- Price
- CRGX $4.07
- DHF $2.53
- Analyst Decision
- CRGX Hold
- DHF
- Analyst Count
- CRGX 7
- DHF 0
- Target Price
- CRGX $4.67
- DHF N/A
- AVG Volume (30 Days)
- CRGX 773.9K
- DHF 451.1K
- Earning Date
- CRGX 03-12-2025
- DHF 01-01-0001
- Dividend Yield
- CRGX N/A
- DHF 7.65%
- EPS Growth
- CRGX N/A
- DHF N/A
- EPS
- CRGX N/A
- DHF N/A
- Revenue
- CRGX N/A
- DHF N/A
- Revenue This Year
- CRGX $119.08
- DHF N/A
- Revenue Next Year
- CRGX N/A
- DHF N/A
- P/E Ratio
- CRGX N/A
- DHF N/A
- Revenue Growth
- CRGX N/A
- DHF N/A
- 52 Week Low
- CRGX $3.00
- DHF $2.06
- 52 Week High
- CRGX $25.45
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- CRGX 40.37
- DHF 41.51
- Support Level
- CRGX $3.98
- DHF $2.50
- Resistance Level
- CRGX $4.25
- DHF $2.57
- Average True Range (ATR)
- CRGX 0.22
- DHF 0.03
- MACD
- CRGX 0.16
- DHF 0.00
- Stochastic Oscillator
- CRGX 36.84
- DHF 41.71
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.